Perry Baromedical Introduces the SIGMA 36 Monoplace Hyperbaric Chamber to the Industry

    /24-7PressRelease/ - RIVIERA BEACH, FL, July 03, 2008 - Perry Baromedical is pleased to announce the product launch and availability of the SIGMA 36 Hyperbaric Chamber. The new SIGMA 36 expands Perry's already broad line of Hyperbaric Therapy Chambers, including monoplace, dualplace and multiplace systems. For over 20 years, Perry Baromedical has held the honor of manufacturing the largest monoplace chamber in the market. The addition of the SIGMA 36 offers the added distinction of creating the two largest monoplace chambers available worldwide. The Company's monoplace chamber line includes the SIGMA 34, the SIGMA 36, with a true 36" internal diameter, and the SIGMA 40, with an internal diameter of 40.5". Perry Chambers are recognized and used worldwide, with an impressive and unrivaled safety record of over 5 million treatment hours performed without incident. For over 40 years Perry Baromedical has been designing, manufacturing and perfecting its hyperbaric systems. This specialized knowledge and expertise in hyperbaric engineering, coupled with consistent, reliable performance has built a loyal customer base and insured Perry's position as a global market leader.

Patient Comfort and Compliance Promotes Positive Clinical Outcome
The larger chamber sizes provide the patient with a more pleasant treatment experience. Confinement anxiety and other complications of patient non-compliance will be reduced if treatment is performed in the larger, more patient friendly chambers. Perry believes that it is not enough to simply make and deliver a product, it is essential to understand and offer new products which better address the needs of healthcare professionals and the patients they serve.
"Ensuring patient comfort while inside the chamber is vital to the clinical outcome of the patient", says Wayne McCullough, President and COO of Perry Baromedical. "Accordingly, positive patient compliance plays a strong role in revenue outcomes as well." An average hyperbaric treatment cycle represents $10,000 in revenue per patient. Poor patient compliance signifies lost revenue for the service provider. The expansion of Perry Baromedical's product line is part of a comprehensive initiative to develop product offerings that promise improved results, both clinically and fiscally.

Hyperbaric Oxygen Therapy Has Become a Standard Medical Treatment
Currently, there are 13 approved conditions that Hyperbaric Oxygen Therapy (HBOT) can benefit, including chronic non-healing wounds, carbon monoxide poisoning and decompression sickness. The World Health Organization (WHO) estimates that approximately 10% of the estimated 180 million people worldwide who suffer from diabetes will be afflicted with chronic non-healing wounds. By administering pure oxygen in a pressurized chamber, the body absorbs 10-15 times more oxygen then if delivered at sea level, promoting the body's natural healing mechanisms. HBOT is a non-invasive, cost effective and safe treatment modality which has been proven successful in decreasing patient cost and increasing the patients' quality of life.

FOR MORE INFORMATION ABOUT PERRY BAROMEDICAL, PLEASE VISIT: http://www.perrybaromedical.com

About Perry Baromedical Corporation

For over 40 years Perry Baromedical Corporation has been the worldwide leader in Hyperbaric Oxygen Therapy Systems. Perry is the only company to engineer, manufacture, install and service monoplace, dualplace and multiplace hyperbaric chambers. Perry also holds the distinguished honor of manufacturing the largest monoplace hyperbaric chamber available today. Over 5,000,000 hours of safe treatment have been performed in Perry chambers worldwide. For more information please visit http://www.perrybaromedical.com

# # #